Treating sickle cell disease
Sickle cell disease is treated by administering a 5-lipoxygenase inhibitor.
1. A method for treating sickle vasocclusive disease which comprises administering to a patient in need thereof zileuton or a pharmaceutically acceptable salt thereof in an amount effective for treating sickle vasocclusive disease.
2. The method of claim 1 wherein the sickle vasocclusive disease is sickle cell anemia.
3. The method of claim 1 wherein the sickle vasocclusive disease is sickle thalassemia.
4. A method of treating sickle vasocclusive disease which comprises administering to a patient in need thereof zileuton or a pharmaceutically acceptable salt thereof in an amount sufficient to increase the production of fetal hemoglobin in normal and sickle red blood cells.
5. A method of treating sickle vasocclusive disease which comprises administering to a patient in need thereof zileuton or a pharmaceutically acceptable salt thereof in an amount sufficient to enhance the expression of gamma globin messenger RNA.
6. A method of treating sickle vasocclusive disease which comprises administering to a patient thereof zileuton or a pharmaceutically acceptable salt thereof in an amount sufficient to decrease activated-neutrophil mediated sickle red blood cell retention in lung circulation.
7. The method of claim 1 wherein acute chest syndrome and pain crisis in sickle vasocclusive disease is treated.